440 results
8-K
EX-99.1
NKTR
Nektar Therapeutics
8 Aug 24
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
4:20pm
of 2023. R&D expense decreased for the first half of 2024 primarily due to decreases in employee costs and related facilities costs as well as development … of facilities costs allocated to research and development expenses partially offset by a decrease in employee costs.
Non-cash restructuring and impairment
8-K
EX-99.1
NKTR
Nektar Therapeutics
9 May 24
Nektar Therapeutics Reports First Quarter 2024 Financial Results
4:20pm
decreased primarily due to a decrease in employee costs and related facilities costs, partially offset by an increase in expense for the development
8-K
EX-99.1
66etx8dmovlz3m
4 Mar 24
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
4:20pm
8-K
EX-10.1
gsl yta1hkpt4jaud367
4 Mar 24
Entry into a Material Definitive Agreement
8:40am
8-K
khlf9stbc0l4lyy
22 Jun 23
Departure of Directors or Certain Officers
8:12pm
8-K
8yx7l
17 Apr 23
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
5:19pm
8-K
EX-3.1
xly6z5vvmbl7 w1ej5ii
16 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:05pm